

Remarks / Arguments


Sequence Listing:

A substitute copy of the sequence listing in both print and computer readable form (CRF), is submitted herewith. The sequence listing in both print and computer readable form that was filed with the parent application included errors, and those errors were subsequently corrected by resubmitting both. Applicants are uncertain whether the corrections provided in the parent case are transferred to this divisional application or if a new submittal of both is necessary. In order to assist in moving this application forward to examination, this corrected sequence listing is resubmitted. Please Note: **The content of both the enclosed paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing are the same and include no new matter as required by 37 CFR 1.821(e) or 37 CFR 1.821(f) or 37 CFR 1.821(g) or 37 CFR 1.825(b) or 37 CFR 1.825(d).**

Claims:

New claims 24-33 are directed to IL-2 muteins having a substitution at position 20. This IL-2 mutein was one of three species restricted out in Paper Number 18 of the parent application.

Respectfully submitted,



John W. Mahoney
April 15, 2004

4-16-04

Reg. No. 44,892
Phone: 510 705-7725

Patent Counsel
Bayer Pharmaceuticals Corporation
Law and Patent Department
P.O. Box 1986
Berkeley, California 94701-1986